Sonoma Operating Cycle from 2010 to 2026
| SNOA Stock | USD 3.03 0.03 0.98% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 195.05 | Current Value 130.63 | Quarterly Volatility 44.02551113 |
Check Sonoma Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sonoma Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 118 K, Interest Expense of 13.7 K or Selling General Administrative of 13.1 M, as well as many indicators such as Price To Sales Ratio of 0.21, Dividend Yield of 0.0 or PTB Ratio of 0.58. Sonoma financial statements analysis is a perfect complement when working with Sonoma Pharmaceuticals Valuation or Volatility modules.
Sonoma | Operating Cycle | Build AI portfolio with Sonoma Stock |
Analyzing Sonoma Pharmaceuticals's Operating Cycle over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Operating Cycle has evolved provides context for assessing Sonoma Pharmaceuticals's current valuation and future prospects.
Latest Sonoma Pharmaceuticals' Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of Sonoma Pharmaceuticals over the last few years. It is Sonoma Pharmaceuticals' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sonoma Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
Sonoma Operating Cycle Regression Statistics
| Arithmetic Mean | 166.62 | |
| Geometric Mean | 161.96 | |
| Coefficient Of Variation | 26.42 | |
| Mean Deviation | 32.52 | |
| Median | 151.06 | |
| Standard Deviation | 44.03 | |
| Sample Variance | 1,938 | |
| Range | 179 | |
| R-Value | 0.53 | |
| Mean Square Error | 1,492 | |
| R-Squared | 0.28 | |
| Significance | 0.03 | |
| Slope | 4.60 | |
| Total Sum of Squares | 31,012 |
Sonoma Operating Cycle History
About Sonoma Pharmaceuticals Financial Statements
Sonoma Pharmaceuticals stakeholders use historical fundamental indicators, such as Sonoma Pharmaceuticals' Operating Cycle, to determine how well the company is positioned to perform in the future. Although Sonoma Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Sonoma Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Sonoma Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Sonoma Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 195.05 | 130.63 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sonoma Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonoma Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonoma Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonoma Pharmaceuticals Stock:Check out the analysis of Sonoma Pharmaceuticals Correlation against competitors. For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Sonoma Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (2.01) | Revenue Per Share | Quarterly Revenue Growth 0.566 | Return On Assets | Return On Equity |
Investors evaluate Sonoma Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Sonoma Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Sonoma Pharmaceuticals' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Sonoma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Sonoma Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.